Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists
Inversago Pharma has raised $69.3M in total funding. The most recent round was Series C. The last funding was announced in October 2022.
Inversago Pharma's investors include New Enterprise Associates, Fonds de solidarité FTQ, Forbion Capital Partners, AQC Capital, adMare Bio Innovations.
Inversago Pharma is headquartered in Montréal, Canada.
Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists
Inversago Pharma is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Inversago Pharma — Funding & Investors." VCBacked, October 17, 2022, https://www.vcbacked.co/company/inversago-pharma. Accessed August 1, 2026.
VCBacked. (2022). Inversago Pharma — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/inversago-pharma
{{cite web |title=Inversago Pharma — Funding & Investors |url=https://www.vcbacked.co/company/inversago-pharma |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated